Compare American Financial Group Inc (AFG) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? American Financial Group Inc trades at $144.65 (market cap $11.97B), while Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.5× American Financial Group Inc's market cap, and American Financial Group Inc pays a 2.44% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| AFG | ALNY | |
|---|---|---|
Market Cap | $11.97B | $29.60B |
Sector | Financials | Health |
52-Week High | $148.71 | $491.22 |
52-Week Low | $124.18 | $205.48 |
Enterprise Value | $12.35B | $27.56B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $144.77, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.82 per share, beating estimates, driven by property and casualty underwriting and investment income. Revenue for 2025 was $8.12 billion with a net income margin of 10.37%, while 2026 projections show improved profitability. A dividend of $0.88 per share is scheduled for payment in July 2026.
AFG presents a positive outlook with analyst consensus price target of $160.67, implying potential upside. Strengths include consistent earnings beats and robust ROE of 20.41%. Risks involve earnings volatility, as seen in Q1 2026 miss, and competitive insurance market pressures. Institutional activity is mixed, with some reducing holdings while others increase positions. The stock is a hold for growth-oriented investors monitoring earnings consistency.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
